Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.
Though no tau-targeted therapy has yet to demonstrate definitive clinical benefit, continued research supports tau as an important therapeutic target and contributes to the development of more effective treatments for AD.
A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...
Lian-Jing Xu, Ying Zhang, Li Jiang et al.· Frontiers in Cellular Neuros...· 0 citations
The current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease is reviewed and modern approaches for diagnosis and treatment are discussed.
Zahraa Mohammed Fakheir, S. A. H. Jasim· Journal of Genetic and Envir...· 0 citations
The development of scalable iPSC-neuron models enables tauopathy drug discovery and reconstructs progressive Tau seeding, fibrillization and synaptic dysfunction, and establishes a physiologically relevant, scalable platform for therapeutic screening that connects Tau seed uptake, site-specific phosphorylation, fibril...
J. Lipka, Xiwei Shan, Qiao Zhang et al.· bioRxiv· 0 citations
While amyloid-β (Aβ) has historically dominated the research landscape of Alzheimer’s disease (AD), the limited clinical success of Aβ-centric therapies has redirected focus toward tau pathology, which correlates more robustly with cognitive deterioration and synaptic dysfunction. Transcending the traditional linear...
Xue Li, Lei-Han Zhang, Li-Jun Zhao et al.· Journal of Translational Med...· 0 citations
Recent progress in tau seeding research is summarized, highlighting both intrinsic and extrinsic regulators of tau prion-like activity and therapeutic strategies targeting tau pathology.
Jin Miao, Chun-Hong Xue, Xu Yan et al.· Frontiers in Neuroscience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
